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Retroviruses have been extensively used in the development of gene transfer systems. Recently, there has been a great
deal of interest in the use of lentiviruses for gene transfer because they infect nondividing cells. Human immunodeficiency
virus (HIV) has been the lentivirus most often used for this purpose, but its genomic complexity and limited tropism present
some challenges to the establishment of efficient gene transfer systems. In this paper we present data showing intrinsic
differences between the infectivity of wild-type HIV and HIV particles pseudotyped with heterologous envelope glycoproteins.
Interestingly, HIV pseudotypes with envelope glycoproteins from the amphotropic murine leukemia virus or the vesicular
stomatitis virus (VSV) are 3 and 40 times more infectious than wild-type HIV, respectively. In addition, we show that the
reliance on Nef expression for maximal infectivity of HIV particles is dependent on the path of virus entry. The dependence
on Nef for higher infectivity is greater for amphotropic pseudotypes and wild-type HIV than for VSV-G pseudotypes. We
conclude that VSV-G pseudotypes of HIV vectors are an excellent choice for gene transfer purposes and Nef-mediated viral
infectivity enhancement is affected by virus entry pathway. © 1998 Academic Press
INTRODUCTION
Recently there has been a great deal of interest in the
development of lentivirus-based gene transfer systems
because they transduce nondividing cells (Bartz et al.,
1996; Lewis et al., 1992; Reiser et al., 1996; Spina et al.,
1995; Von Schwedler et al., 1994; Weinberg et al., 1991).
The lentivirus systems with the most promising results to
date are those based on the human immunodeficiency
virus (HIV) (Fauci, 1988). However, HIV is a complex
retrovirus that in addition to the gag, pol, and env genes
present in other retroviruses contains several additional
regulatory and ancillary genes (Luciw, 1996). The role of
the ancillary genes is not clear and their phenotype is not
obvious under all experimental conditions (Cullen, 1994;
Trono, 1995). One of these genes, nef, is of particular
interest to the development of HIV-based gene transfer
systems because it has been shown to enhance the
infectivity of HIV and simian immunodeficiency virus
(SIV) particles (Miller et al., 1994; Spina et al., 1994). We
have previously reported significant differences in the
magnitude of the infectivity enhancement mediated by
Nef between different HIV isolates (Luo and Garcia,
1996). These results highlight the importance of a careful
choice of provirus for the establishment of a gene trans-
fer system.
The nef genes of HIV and SIV encode a 27- to 34-kDa
myristoylated phosphoprotein (Allan et al., 1985; Bandres
et al., 1994; Colombini et al., 1989; Guy et al., 1987; Luo et
al., 1997; Shibata et al., 1990). Together with the regula-
tory proteins Tat and Rev, Nef is expressed early during
infection (Kim et al., 1989; Klotman et al., 1991; Munis et
al., 1992; Robert-Guroff et al., 1990). Nef plays a crucial
role in the maintenance of high virus load and the sub-
sequent development of AIDS in adult macaques in-
fected with SIV (Kestler et al., 1991). The significance of
Nef in virus replication has also been highlighted in
studies using a SCID-hu mouse model of HIV infection
(Aldrovandi and Zack, 1996; Jamieson et al., 1994). Con-
sistent with an important role for Nef in HIV infection,
several long-term nonprogressors have been found to be
infected with nef-defective viruses (Deacon et al., 1995;
Kirchhoff et al., 1995). All of these in vivo findings suggest
an important role for Nef in HIV replication and the
development of AIDS.
In vitro studies have shown that Nef downregulates
cell surface expression of CD4, the main receptor for
both HIV and SIV (Bates, 1996; Dalgleish et al., 1984;
Kannagi et al., 1985; Klatzman et al., 1984; Landau et al.,
1988; Maddon et al., 1986). Nef downregulates cell sur-
face CD4 expression and decreases total cellular CD4
levels by accelerating its endocytosis and its subsequent
degradation in lysosomes (Aiken et al., 1994; Anderson
et al., 1994, 1993; Benson et al., 1993; Foster, 1994; Garcia
and Miller, 1991; Guy et al., 1987; Luo et al., 1996; Mariani
and Skowronski et al., 1993; Rhee and Marsh 1994). Nef
also enhances viral infectivity and viral growth in vitro
(Miller et al., 1994; Spina et al., 1994). Upregulation of
viral growth by Nef has been reported to be mediated
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through an increase in proviral DNA synthesis (Aiken
and Trono, 1995; Schwartz et al., 1995), but for the most
part the mechanism of infectivity enhancement remains
unknown.
In this report, we compared the infectivity of wild-
type HIV particles to that of similar particles
pseudotyped with envelope glycoproteins from the
amphotropic murine leukemia virus (MLV) or vesicular
stomatitis virus (VSV). In addition, we determined
whether the different pseudotypes exhibited the Nef-
dependent infectivity enhancement seen with wild-
type HIV. Our results show that both the amphotropic
and VSV envelope pseudotypes are significantly more
infectious than wild-type HIV and that the dependence
on Nef for infectivity enhancement effect is higher for
amphotropic pseudotypes and wild-type HIV than for
VSV-G pseudotypes.
RESULTS
VSV-G and amphotropic envelope pseudotyped HIV
are more infectious than wild type
Replication-defective HIV-based retroviral vectors are
currently been evaluated for their potential use as gene
transfer vehicles (Carroll et al., 1994; Corbeau et al., 1996;
Page et al., 1990; Parolin et al., 1996; Poznansky et al.,
1991; Shimada et al., 1991). Because HIV infects predom-
inantly CD41 cells, heterologous viral glycoproteins have
been used to improve their tropism (Akkina et al., 1996;
Landau et al., 1991; Naldini et al., 1996). The infectivities
of these pseudotyped retroviruses are determined to a
large extent by the type of viral envelope glycoproteins
on their surface. Using a simple one-cycle infection as-
say, we compared the relative infectivity of wild-type HIV
particles with those pseudotyped with the envelope gly-
FIG. 1. Diagram of HIV proviruses and amphotropic and VSV-G envelope expression constructs. (Top) LAI, wild-type infectious provirus; LAIDN, LAI
with a fame shift (fs) in the nef gene; LAIDE, LAI with a 580-bp BglII deletion in the envelope gene; LAIDEDN, LAI with a deletion in the envelope gene
and a frame shift in the nef ORF. (Bottom) Diagram of VSV-G and amphotropic MLV envelope expression constructs. The VSV-G gene is driven by an
HIV long terminal repeat (LTR). The amphotropic murine leukemia virus envelope glycoprotein expression construct is driven by the Moloney MLV
LTR. SA-PA, SV40 polyadenylation signal; SVori, SV40 origen of replication.
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coproteins from amphotropic MLV or VSV. Infectious par-
ticles were generated in 293T cells by transfection of the
provirus HIV-1LAI (LAI) or by cotransfection of an LAI
derivative deleted in the envelope gene (LAIDE) with a
construct that expressed either of the heterologous en-
velope glycoproteins (Fig. 1). When normalized for p24
content, a measure of virus particles, both of the
pseudotyped viruses were significantly more infectious
than wild type HIV (Fig. 2). Amphotropic pseudotyped
particles were 3 times more infectious than the wild-type
HIV and VSV-G pseudotyped particles were 40 times
more infectious than the wild-type virus in HeLa-MAGI
cells (Fig. 2A). These differences in infectivity were re-
produced several times in independent experiments with
different virus preparations (data not shown). Next we
compared the relative infectivity of wild-type HIV with
amphotropic and VSV-G pseudotyped particles in U937
cells by scoring their ability to downregulate cell surface
CD4 expression (Aiken et al., 1994; Chen et al., 1996).
U937 cells were infected with equal amounts of p24 from
the wild-type, amphotropic, and VSV-G pseudotyped vi-
ruses. To prevent replication of the wild-type virus, AZT
was added 16 h postinfection. As shown in Fig. 2B,
VSV-G and amphotropic pseudotyped particles were 6.3
and 1.7 times more infectious than wild-type HIV (Fig. 2B).
The differences in infectivity observed in U937 cells
among the three viruses are likely to be underestima-
tions because much higher levels of infectious particles
had to be used to obtain reasonable amounts of cells
transduced by wild-type HIV. It should be noted that
particles produced with LAIDE alone (devoid of envelope
glycoprotein) were not infectious in this assay (data not
shown). These data indicate that replacement of the HIV
envelope glycoprotein with those from the amphotropic
MLV or VSV not only broadens the viral tropism but also
significantly enhances viral infectivity.
Infectivity of VSV-G pseudotypes is neutralized by
VSV-specific antibodies and inhibitors of endosome/
lysosome acidification
VSV-G has a very strong fusiogenic effect that can
result in cell lysis followed by release of intracellular
proteins. Because the release of intracellular proteins
FIG. 2. VSV-G and amphotropic pseudotypes are more infectious than HIV-1 particles. (A) One nanogram p24 wild-type or amphotropic and 0.02
ng p24 VSV-G pseudotyped virus were used to infect HeLa-MAGI cells. Cells were fixed 36 h postinfection and stained with X-Gal, and the number
of infected (blue) cells was determined. The experiment was performed in triplicate and repeated at least twice. The number of blue cells obtained
with the VSV-G pseudotype was normalized to 1 ng p24. Results are shown as the percentage of the number of infected cells obtained with LAI
(designated 100%). (B) U937 cells (5 3 105) were infected with wild-type, amphotropic, or VSV-G pseudotypes (80 ng p24 each) in the presence of 20
mg/ml DEAE-dextran (Sigma). Four hours postinfection cells were washed three times with cell culture medium and the infected cells were cultured
in a 12-well plate. At 16 h postinfection, AZT (50 mM final concentration) was added to the infected cells. CD4 cell surface expression levels were
analyzed by flow cytometry 48 h postinfection. CD4 cell surface downregulation obtained with LAI (7.8%) was designated 1. The data represent the
average of two determinations.
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from the producer cells could result in artificially high
scores in our assay, we sought confirmation of retrovi-
rus-mediated transduction. For this purpose we first de-
termined if neutralizing antibodies specific for VSV would
inhibit transduction by the HIV(VSV-G) pseudotypes. As
shown in Fig. 3A the VSV-specific antibodies inhibited
transduction in a concentration-dependent manner. In
addition, Bafilomycin A1, a specific inhibitor of the vesic-
ular ATPase required for the acidification of late endo-
somes, reduced the infectivity of the VSV-G pseudotypes
to background levels (Fig. 3B). These results are consis-
tent with the interaction of VSV-G with its receptor for
entry and with the required acidification of endosomes to
facilitate the VSV-G-induced fusion of the virus mem-
brane with the vesicular membrane prior to the release
of the virus core into the cytosol.
Nef does not enhance virus production
Nef has been shown to enhance virus infectivity and a
recent report suggests that Nef also increases virus
production after transfection by approximately fivefold
(Lu et al., 1996). To determine if the increase in infectivity
associated with the VSV-G pseudotypes also coincided
with an increased production of Nef1 viruses, the levels
of virus particles produced by LAI, LAIDE(VSV-G), and
their respective nef 2 constructs were compared. As
shown in Fig. 4, there was no correlation between higher
levels of virus particle production and Nef expression for
either wild-type HIV or the VSV-G pseudotypes. These
results are in agreement with a model suggesting that
Nef acts post viral entry and does not affect the levels of
particles produced by the transfected cells.
HIV(VSV-G) pseudotypes are less dependent on Nef
for maximal infectivity
Different viruses enter target cells through different
mechanisms. HIV enters permissive cells by direct fu-
sion between the viral envelope and the cellular mem-
brane (Luciw, 1996; Bates, 1996). VSV enters target cells
through receptor-mediated endocytosis (Matlin et al.,
1982). To examine whether the Nef-mediated viral infec-
tivity enhancement is affected by the entry pathway, the
infectivities of wild-type, amphotropic and VSV-G
pseudotyped HIV particles were compared to their cor-
responding Nef-defective counterparts. As shown in Fig.
5 virus particles obtained with LAI (expressing Nef) were
10 times more infectious than particles obtained with LAI
DN (Nef-defective). A 20-fold higher infectivity was ob-
served with the amphotropic pseudotyped HIV contain-
ing Nef. Interestingly, VSV-G pseudotyped particles ob-
tained from the nef 1 provirus only showed an infectivity
3-fold higher than that of VSV-G pseudotyped particles
FIG. 3. Infectivity of VSV-G pseudotypes is neutralized by VSV-specific antibodies and an inhibitor of endosome/lysosome acidification. (A)
HeLA-MAGI cells were infected with LAIDE(VSV-G) in the presence of VSV-specific antisera (closed triangles) or normal rabbit sera (open squares).
The results are presented as the percentage of infected cells obtained in the absence of both sera (100%). (B) HeLa-MAGI cells were pretreated with
100 nM BFLA1 (Sigma, St. Louis) for 50 min and then infected by the viruses also in the presence of BFLA1. The medium was replaced 20 h
postinfection and the cells were incubated without the inhibitor for an additional 16 h before fixing and staining with X-Gal as described in the legend
to Fig. 2.
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obtained with the nef-defective provirus. These data sug-
gest that Nef-mediated viral infectivity enhancement is
affected by the pathway used by the virus to enter the
target cell.
DISCUSSION
In vivo studies have demonstrated the importance of Nef
in HIV and SIV replication and pathogenesis (Jamieson et
al., 1994; Kestler et al., 1991). In vitro, Nef has been shown
to have at least two independent functions: downregulation
of cell surface antigens like CD4 and MHC I and the
enhancement of viral infectivity (Garcia and Miller, 1991;
Goldsmith et al., 1995; Guy et al., 1987; Iafrate et al., 1997;
Luo and Garcia, 1996; Miller et al., 1994; Spina et al., 1994;
Schwartz et al., 1996). However, the precise mechanisms
underlying these functions of Nef are largely unknown. For
the development of HIV-based gene transfer systems the
role of Nef in infectivity enhancement is of great interest.
Whereas Nef expression might result in a more infectious
particle, inclusion of nef in the packaging construct is likely
to result in generation of significant levels of replication-
competent helper virus. The overlap of nef with 39-LTR
sequences could allow recombination between packaging
constructs and vectors. The obvious alternative to introduc-
ing nef in a separate construct is not trivial because the
establishment of Nef expressing cells with systems other
than retrovirus vectors has proven to be difficult (Baur et al.,
1994). However, because of the significant differences in
the dependence on Nef expression for maximum infectivity
between different HIV proviruses (Luo and Garcia, 1996), an
obvious alternative is to use a provirus that in the absence
of Nef is still highly infectious. One good example is LAI
(Wain-Hobson et al., 1985). As shown here, Nef-defective
LAI is only about 8–10 times less infectious than wild type.
In contrast, another laboratory strain, SF2 (Sanchez-Pesca-
dor et al., 1985), is 40 times less infectious without Nef (Luo
and Garcia, 1996).
One obvious and significant limitation of packaging
systems that incorporate the HIV envelope is their very
limited tropism to CD41 cells. An additional limitation is
the requirement of specific coreceptor molecules by dif-
ferent strains of virus (Bates, 1996). The use of pseudo-
types is appealing because it expands the tropism of the
vectors and it minimizes the chance of producing recom-
binant replication-competent helper viruses. In this study
we compared an amphotropic MLV envelope glycopro-
tein and a VSV glycoprotein pseudotype to wild-type HIV.
The first interesting observation made was that both
pseudotyped particles were significantly more infectious
than wild-type HIV. The amphotropic and VSV-G
pseudotypes were 3 to 40 times more infectious than
wild-type HIV, respectively, in the HeLa-MAGI aasay. Al-
though less than in the HeLa-MAGI assay, the VSV-G and
amphotropic pseudotyped particles were also found
more infectious than wild-type HIV in U937 human mono-
cyte cells. This higher infectivity/ng of p24 of the
pseudotyped particles is further evidence supporting
their use in the development of HIV-based gene transfer
systems.
The second significant observation made with these
pseudotypes was that in the absence of Nef both the
wild-type particles and the amphotropic pseudotypes
were much less infectious than the VSV-G pseudotypes.
Surprisingly, the difference in infectivity between the
FIG. 4. Nef does not affect HIV particle production. (A) Western blot
analysis of Nef expression. Equal amounts of total cellular proteins (100
mg) from provirus transfected 293T cells were separated by SDS–
PAGE, transferred to a nitrocellulose membrane, and probed with rabbit
anti-Nef sera followed by goat anti-rabbit IgG conjugated with alkaline
phosphatase. Lanes 1 to 4, cell lysates from cells transfected with LAI
(lane 1); LAIDN (lane 2); LAIDE(VSV-G) (lane 3); and LAIDEDN(VSV-G)
(lane 4). The molecular mass marker is indicated on the left (in kilo-
daltons). (B) HIV production as determined by p24 production after
transfection of the indicated proviruses. This experiment was repeated
twice with similar results.
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Nef1 and Nef2 viruses was only threefold when
pseudotyed with VSV-G. This increase in the infectivity of
the Nef-defective particles is highly significant because it
not only ameliorates the need for Nef in obtaining high
titer virus, but it also sheds light on the mechanism of
Nef function by suggesting that the effect of Nef on viral
infectivity enhancement is dependent on the pathway of
virus entry. These two findings are in agreement with
Aiken’s recently published results with a different virus
(Aiken, 1997)
Currently available data support the notion that HIV
particles and amphotropic pseudotypes enter cells by
direct fusion with the cell membrane (Fig. 6) (Bates, 1996;
Coffin, 1996; Luciw, 1996). These particles deposit their
genetic material directly into the cytoplasm in the form of
a preintegration complex. This protein–nucleic acid com-
plex subsequently traverses to the nucleus where the
reverse-transcribed provirus integrates into a cell chro-
mosome (Bukrinskaya et al., 1996; Luciw, 1996; Steven-
son, 1996). VSV-G pseudotypes take a different route to
the cell nuclei. VSV-G pseudotypes enter the target cells
via receptor-mediated endocytosis and follow this path-
way until they encounter an acidic environment where
the low pH conditions favor the VSV-G-mediated fusion
of the virus and the endosome membranes. Treatment of
target cells with a highly specific inhibitor of the proton
pump responsible for the acidification of late endosomes
and lysosomes completely blocks infection by the VSV-G
pseudotypes (Fig. 5). These results indicate that depend-
ing on how the virus enters the cell, one can observe a
more or less pronounced dependence on Nef for infec-
tivity. This suggests that the effect of Nef on infectivity
enhancement is dependent on the route which the pro-
virus takes to the nuclei. The molecular bases for these
differences are not clear but the data presented will form
the basis for future experiments aimed at their elucida-
tion. A clear understanding of Nef function will facilitate
the development of Nef inhibitors that might be used to
prevent virus spread and as tools to dissect the interac-
tions between the cell and HIV. For the practical pur-
poses of developing HIV-based gene transfer systems
our results encourage efforts to develop stable producer
lines based on VSV-G pseudotypes. While this might not
be an easy and simple task, the improvements that it is
likely to provide in titer, tropism, and stability of vector
particles should be worth the effort.
MATERIALS AND METHODS
Cell lines and culture conditions
Human 293T and HeLa-CD4-LTR-b-Gal (HeLa-
MAGI) cells were cultured in DMEM supplemented
FIG. 5. HIV(VSV-G) pseudotypes are less dependent on Nef for maximal infectivity. (A) Viral Infectivity enhancement by Nef of wild-type (WT) or
amphotropic (AMPHO) pseudotyped virus particles. (B) Viral infectivity enhancement by Nef of VSV-G pseudotyped virus particles. These experiments
were conducted, as in Fig. 2, in triplicate and repeated at least twice with similar results. (C) Nef-mediated viral infectivity enhancement (fold). These
bars represent the ration of Nef1/2 virus infection from panels A and B.
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with 50 IU penicillin, 50 mg/ml streptomycin, and 10%
FBS. U937 cells were cultured in RPMI 1640 medium
with 25 mM N-2-hydroxyethylpiperazine-N’-2-ethane-
sulfonic acid (HEPES) supplemented with 10% fetal
bovine serum (FBS) (Hyclone, Logan, UT), 50 IU of
penicillin, 50 mg of streptomycin/ml, 2 mM L-glutamine,
and 1 mM sodium pyruvate. Cell lines were main-
tained at 37°C in a humidified incubator with 10%
(293T and HeLA-MAGI) or 5% (U937) CO2.
Analysis of cell surface CD4 expression by flow
cytometry
For flow cytometric analysis, 5 3 105 cells were resus-
pended in a solution of phycoerythrin (PE)-conjugated
monoclonal antibody to human CD4 or isotype-matched
control (both from Exalpha, Boston, MA), diluted in
PBS–5% calf serum (CS), and incubated on ice for 20 min.
Stained cells were washed twice in 2 ml of ice-cold
FIG. 6. Diagram illustrating the differences in the pathways of virus internalization between HIV and HIV(VSV-G) pseudotypes. (Right) Diagram
illustrating wild-type HIV entering the target cell via direct fusion between the viral envelope and the cell membrane. The viral core is deposited into
the cytosol and the viral preintegration complex then travels to the nucleus to continue the viral life cycle. (Left) Diagram illustrating a VSV-G
pseudotyped HIV particle internalized through an endocytotic vesicle. In the low pH environment of endosomes, VSV-G mediates the fusion between
the viral envelope and the endosome membrane prior to the release of the virus core into the cytosol. The viral preintegration complex then travels
to the nucleus to initiate the next step of the viral life cycle. The diagram also illustrates the role of the H1-ATPase pump inhibited by BFLA1 in the
acidification of the endosome.
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PBS–CS and resuspended in PBS with 2% formaldehyde.
The samples were analyzed in a FACSCalibur System
(Becton–Dickinson).
Construction of nef-defective proviruses and
production of virus stocks
The LAI and LAIDE proviruses (kindly provided by M.
Emerman) were digested with XhoI, filled in with Klenow
DNA polymerase, and religated to introduce a frame shift
in the Nef ORF resulting in LAIDN and LAIDEDN. Infec-
tious viruses were prepared in 293T cells (1 3 106)
transfected with the appropriate LAI derivative with or
without addition of a plasmid expressing the ampho-
tropic MLV or the VSV envelope glycoprotein using Lipo-
fectamine-mediated transfection (Life Technologies). Vi-
rus was harvested 48 h posttransfection, filtered through
a 0.45 mM filter, and stored frozen in aliquots at 270°C.
Lysates from the transfected cells were used for analysis
of Nef expression by Western blot as previously de-
scribed (Anderson et al., 1993).
Infectivity assays
HeLa-MAGI cells (6 3 104) were plated in 12-well
plates and infected 24 h later in triplicate with 1 ng p24
of the respective virus stocks except for the VSV-G
pseudotypes, which were titered using 0.02 ng p24 per
infection. Values were then adjusted to reflect infection
with 1 ng p24 for comparison with wild-type HIV and the
amphotropic pseudotypes. Cells were infected with the
appropriate dilution of the different virus preparations in
400 ml of cell culture medium containing 20 mg/ml DEAE-
dextran (Sigma, St. Louis, MO) at 37°C in an incubator
with 8% CO2. Two hours after inoculation, 1.6 ml of culture
medium was added and the cells were incubated for an
additional 36 h. Cells were then fixed and stained as
described previously (Kimpton and Emerman, 1992). Blue
cells were counted as an indicator of infected cells. For
the virus neutralization experiments, viruses were incu-
bated with the appropriate dilution of either control nor-
mal rabbit serum or antiserum to whole VSV (Lee Biomo-
lecular Research Inc. CA). To test the effect of Bafilomy-
cin A1 (BFLA1) on the infectivity of the VSV-G
pseudotypes, cells were incubated with BFLA1 for 50
min prior to the addition of the virus. Medium was
changed the next day and cells were stained 24 h later
as described above. U937 cells (5 3 105) were infected
with wild type, amphotropic, or VSV-G pseudotypes (80
ng p24 each) in the presence of 20 mg/ ml DEAE-dextran
(Sigma). Four hours postinfection cells were washed
three times with cell culture medium and the infected
cells were cultured in a 12-well plate. At 16 h postinfec-
tion, AZT (50 mM final concentration) was added to the
infected cells.
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